SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist … Read more
SynAct Pharma AB (SYNACT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.000x
Based on the latest financial reports, SynAct Pharma AB (SYNACT) has a cash flow conversion efficiency ratio of 0.000x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-18.79K) by net assets (Skr196.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SynAct Pharma AB - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how SynAct Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SynAct Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SynAct Pharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyungbangco.Ltd
KO:000050
|
0.017x |
|
Gabriel Holding A/S
F:1GH
|
0.144x |
|
RESEARCH SOLUTIONS DL-001
F:61I
|
N/A |
|
NANOFORM FINLAND OYJ
F:4YL
|
N/A |
|
Akenerji Elektrik Uretim AS
IS:AKENR
|
0.044x |
|
Namyong Terminal PCL
BK:NYT
|
0.085x |
|
Velan Inc
PINK:VLNSF
|
-0.043x |
|
Minaurum Gold Inc
OTCQX:MMRGF
|
-0.431x |
Annual Cash Flow Conversion Efficiency for SynAct Pharma AB (2016–2024)
The table below shows the annual cash flow conversion efficiency of SynAct Pharma AB from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr214.17 Million | Skr-89.20 Million | -0.416x | +26.75% |
| 2023-12-31 | Skr176.19 Million | Skr-100.18 Million | -0.569x | +38.81% |
| 2022-12-31 | Skr126.52 Million | Skr-117.56 Million | -0.929x | +70.17% |
| 2021-12-31 | Skr20.87 Million | Skr-65.00 Million | -3.115x | -48.68% |
| 2020-12-31 | Skr15.87 Million | Skr-33.24 Million | -2.095x | -75.44% |
| 2019-12-31 | Skr13.50 Million | Skr-16.12 Million | -1.194x | +49.15% |
| 2018-12-31 | Skr10.31 Million | Skr-24.21 Million | -2.348x | -76.25% |
| 2017-12-31 | Skr12.91 Million | Skr-17.20 Million | -1.332x | -144.84% |
| 2016-12-31 | Skr27.08 Million | Skr-14.73 Million | -0.544x | -- |